Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,240 matching trials from the live ClinicalTrials.gov search.
Conditions
Polycythemia Vera
Interventions
XL019
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 2 more
Conditions
Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions
PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more
Conditions
Healthy Subjects
Interventions
fosamprenavir + ritonavir + methadone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Buffalo, New York
Completed Phase 1 Interventional

BN83495 in Prostate Cancer

NCT00790374
Conditions
Prostate Cancer
Interventions
BN83495 (Cohort 1), BN83495 (Cohort 2), BN83495 (Cohort 3)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Madison, Wisconsin
Conditions
Myeloproliferative Disorders, Myelofibrosis, Polycythemia Vera, Thrombocythemia, Essential
Interventions
XL019
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • Boston, Massachusetts + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD

NCT03744182
Conditions
NAFLD
Interventions
HM15211, Placebo of HM15211
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Solid Tumor
Interventions
ASN004
Drug
Lead sponsor
Kirilys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Austin, Texas • San Antonio, Texas + 1 more
Conditions
Arthritis, Rheumatoid
Interventions
BMS-986528
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
La Jolla, California • Loma Linda, California • Palo Alto, California + 7 more
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Month to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Conditions
Glioblastoma
Interventions
RO7428731
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Cancer, Solid Tumors, Lymphoma, Malignancy
Interventions
Debio 1143 (AT-406)
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina
Conditions
Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma, ACC
Interventions
TKM-080301
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more
Conditions
Acne
Interventions
TVB-3567, Placebo
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

NCT00803686
Conditions
Phase 1 Pharmacodynamic Study
Interventions
Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Conditions
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Interventions
MT-8421, Nivolumab
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Midomafetamine in Healthy Adults

NCT07584720
Conditions
Healthy Volunteers
Interventions
Midomafetamine HCl
Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Astrocytoma, Glioblastoma
Interventions
CC-90010
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Boston, Massachusetts
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
Interventions
GEM103
Biological
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more
Conditions
ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eatontown, New Jersey
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Chronic Kidney Disease
Interventions
AZD4248, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Conditions
Semantic Dementia
Interventions
Verdiperstat
Drug
Lead sponsor
Peter Ljubenkov, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more